TLDRs;
- BlackRock stock dips slightly after acquiring a 5% stake in HLB during FDA review of Rivoceranib.
- Rivoceranib faces FDA scrutiny after prior setbacks, though trials show strong survival benefits over existing treatments.
- BlackRock’s HLB purchase signals strategic focus on high-risk, high-fee biotech investments.
- BlackRock’s stock dipped modestly as investors weigh FDA timing and biotech investment risks.
Shares of BlackRock (BLK) experienced a slight decline on Wednesday following the firm’s announcement that it acquired a 5.01% stake in South Korean biotech company HLB. The investment comes as HLB’s liver cancer drug candidate, Rivoceranib, undergoes review by the U.S. Food and Drug Administration (FDA), with a decision expected on July 23, 2026.
According to HLB’s regulatory filing, BlackRock Fund Advisors purchased 6,664,921 shares on the open market as of February 24, citing a straightforward investment purpose. This marks BlackRock’s return to HLB after previously holding a 5.07% stake in December 2020, which it gradually sold off after 2021.
Rivoceranib’s Regulatory Hurdles
The FDA review is a critical milestone for Rivoceranib, which has faced a complex regulatory journey. The therapy has already received two complete response letters (CRLs) from the FDA since May 2024, including concerns tied to an inspection of the camrelizumab manufacturing facility.
Despite these setbacks, clinical trials showed promising results, with a median overall survival of 23.8 months compared with 15.2 months for the standard sorafenib treatment.
Rivoceranib has gained recognition internationally. Both the 2025 Barcelona Clinic Liver Cancer (BCLC) treatment strategy and the European Society for Medical Oncology (ESMO) 2025 guidelines list it as a first-line option.
Additionally, China’s National Medical Products Administration approved the combination therapy in February 2023. The upcoming FDA decision will be a pivotal moment, determining the drug’s potential entry into the U.S. market.
Strategic Shift for BlackRock
This stake in HLB is more than a single-drug play. For BlackRock, traditionally known for low-fee index funds managing roughly $14 trillion in assets, the investment reflects a growing interest in higher-fee and higher-risk sectors.
Private markets revenue has nearly doubled year-on-year to around $2.4 billion in 2025, highlighting the firm’s move toward specialized, fee-generating opportunities.
Industry observers note that concentrated bets like this can validate smaller biotech firms and attract attention from generalist investors. BlackRock’s involvement may encourage other major funds to explore niche sectors, marking a broader trend in asset management where traditional passive strategies increasingly coexist with targeted high-risk plays.
Market Reaction and Outlook
Investors responded cautiously to BlackRock’s stake, contributing to the stock’s minor decline. Analysts suggest that while the market acknowledges BlackRock’s long-term strategy, short-term uncertainty remains due to the pending FDA decision and HLB’s regulatory track record.
Looking ahead, BlackRock’s move could reshape investor sentiment in biotech markets, with its presence potentially accelerating capital flow to firms navigating complex regulatory pathways. The next few months will be closely watched, especially as Rivoceranib approaches its FDA target action date.
Considering a new stock? You may want to see what’s on our watchlist first.
Our team at Knockout Stocks follows top-performing analysts and market-moving trends to spot potential winners early. We’ve identified five stocks gaining quiet attention that could be worth watching now. Create your free account to unlock the full report and get ongoing stock insights.Get 3 Free Stock Ebooks
Discover top-performing stocks in AI, Crypto, and Technology with expert analysis.
- Top 10 AI Stocks - Leading AI companies
- Top 10 Crypto Stocks - Blockchain leaders
- Top 10 Tech Stocks - Tech giants
